CLINICAL_TRIALS
trial_result
· 2014-03-31
Clinical Trial Update: GAUSS: A Study of Obinutuzumab (RO5072759) in Patients With Indolent Non-Hodgkin's Lymphoma [Phase 2]
Summary
Phase 2 GAUSS study evaluating obinutuzumab in patients with indolent non-Hodgkin lymphoma has completed, with results posted in 2014.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Hoffmann-La Roche | Conditions: Non-Hodgkin's Lymphoma | Phase 2 | Status: COMPLETED | Results posted: 2014-03-31